Table 1.
Characteristics of patients used for cytokine and CD23 immunohistochemistry
| Subject no. | Age (year)/sex | Postmortem delay (hr) | Duration of disease (year) | l-dopa treatment (mg/d) | Immediate cause of death |
|---|---|---|---|---|---|
| Cytokine analysis | |||||
| Parkinsonian patients | |||||
| 1 | 64 /M | 4 | 14 | 175 | Bronchopneumonia |
| 2 | 73 /F | 9 | 13 | 625 | Bronchopneumonia |
| 3 | 87 /F | 12 | 2 | 1000 | Bronchopneumonia |
| 4 | 88 /F | 6.75 | 10 | 562.5 | Sepsis |
| 5 | 96 /F | 6.75 | 5 | 650 | Pneumonia |
| Controls | |||||
| 1 | 88 /F | 6 | Bronchopneumonia | ||
| 2 | 82 /M | 11 | Ventricular fibrillation | ||
| 3 | 85 /M | 10 | Bronchopneumonia | ||
| 4 | 89 /F | 6.5 | Bronchopneumonia | ||
| 5 | 53 /M | 11 | Ventricular fibrillation | ||
| 6 | 99 /F | 5 | Bronchopneumonia | ||
| 7 | 70 /M | 12.5 | Ventricular fibrillation | ||
| CD23 analysis | |||||
| Parkinsonian patients | |||||
| 1 | 74 /M | 10 | 17 | 1000 | Bronchopneumonia |
| 2 | 83 /M | 15 | 20 | 500 | Bronchopneumonia |
| 3 | 72 /F | 22 | 30 | 300 | Bronchopneumonia |
| 4 | 72 /M | 29 | 11 | 500 | Bronchopneumonia |
| 5 | 71 /M | 38 | 32 | 1812.5 | Pulmonary embolism |
| 6 | 59 /F | 15 | 21 | 812.5 | Pulmonary embolism |
| 7 | 96 /F | 39 | 6 | 625 | Bronchopneumonia |
| Controls | |||||
| 1 | 85 /M | 10 | Pulmonary embolism | ||
| 2 | 85 /M | 16 | Cardiac insufficiency | ||
| 3 | 63 /M | 22.25 | Gastric bleeding | ||
| 4 | 80 /M | 13.75 | Lung cancer | ||
| 5 | 101 /M | 40.5 | Pulmonary infarction |